Skip to main content

Galapagos to Acquire BioFocus for $36.5M in Stock

NEW YORK, Sept. 21 (GenomeWeb News) - Dutch biotech Galapagos has reached an agreement to acquire UK-based BioFocus for ₤20.2 million ($36.5 million), Galapagos said in a statement today.

 

According to the terms of the offer, Galapagos will buy the entire issued share capital of BioFocus by Oct. 12. BioFocus will then become part of the Galapagos group with a 30 percent stake in the firm.

 

Galapagos CEO Onno van de Stolpe said that the acquisition is expected to enhance the company's position in the drug discovery market.

 

"We are truly impressed by their drug discovery capabilities [and] we believe that these will greatly accelerate our programs in bone and joint diseases," van de Stolpe said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.